Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on October 26, 2009

Hypertension. 2009
Published online before print October 26, 2009, doi: 10.1161/HYPERTENSIONAHA.109.132167
A more recent version of this article appeared on December 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
54/6/1298    most recent
HYPERTENSIONAHA.109.132167v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Xie, C.
Right arrow Articles by Wang, D. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xie, C.
Right arrow Articles by Wang, D. H.
Related Collections
Right arrow Animal models of human disease
Right arrow Other hypertension

Submitted on March 4, 2009
Revised on March 23, 2009

Ablation of Transient Receptor Potential Vanilloid 1 Abolishes Endothelin-Induced Increases in Afferent Renal Nerve Activity. Mechanisms and Functional Significance

Chaoqin Xie and Donna H. Wang*

From the Department of Medicine (C.X., D.H.W.), Neuroscience Program (D.H.W.) and Cell and Molecular Biology Program (D.H.W.), Michigan State University, East Lansing, Mich.

* To whom correspondence should be addressed. E-mail: donna.wang{at}ht.msu.edu.

Abstract—Endothelin 1 (ET-1) and its receptors, ETA and ETB, play important roles in regulating renal function and blood pressure, and these components are expressed in sensory nerves. Activation of transient receptor potential vanilloid (TRPV) 1 channels expressed in sensory nerves innervating the renal pelvis enhances afferent renal nerve activity (ARNA), diuresis, and natriuresis. We tested the hypothesis that ET-1 increases ARNA via activation of ETB, whereas ETA counterbalances ETB in wild-type (WT) but not TRPV1–null mutant mice. ET-1 alone or with BQ123, an ETA antagonist, perfused into the left renal pelvis increased ipsilateral ARNA in WT but not in TRPV1–null mutant mice, and ARNA increases were greater in the latter. [Ala1, 3,11,15]-endothelin 1, an ETB agonist, increased ARNA that was greater than that induced by ET-1 in WT mice only. [Ala1, 3,11,15]-endothelin 1–induced increases in ARNA were abolished by chelerythrine, a protein kinase C inhibitor, but not by H89, a protein kinase A inhibitor. Chelerythrine, H89, and BQ788, an ETB antagonist, did not affect ARNA triggered by capsaicin in WT mice. Substance P release from the renal pelvis was increased by [Ala1, 3,11,15]-endothelin 1 in WT mice only, and the increase was abolished by chelerythrine but not by H89. Chelerythrine, H89, and BQ788 did not affect capsaicin-induced substance P release. Our data show that ET1 increases ARNA via activation of ETB, whereas ETA counterbalances ETB in WT but not in TRPV1-null mutant mice, suggesting that TRPV1 mediates ETB-dependent increases in ARNA, diuresis, and natriuresis possibly via the protein kinase C pathway.


Key words: TRPV1 • ET-1 • ETB receptors • PKC • afferent renal nerve activity